Erythropoietin overview--1993

Area of Science:

• Endocrinology
• Hematology
• Nephrology

Background:

• Endogenous erythropoietin (EPO) biology and its role in red blood cell (RBC) production are increasingly understood.
• EPO deficiency, not inhibitors, is implicated as the cause of anemia in renal patients.
• Recombinant EPO has been clinically available since 1989, with widespread use in dialysis patients.

Purpose of the Study:

• To review current knowledge on EPO biology, recombinant EPO use, and its clinical implications.
• To discuss factors influencing EPO production and response, including oxygen consumption and secondary hyperparathyroidism.
• To explore the benefits and side effects of recombinant EPO therapy in renal failure patients.

Main Methods:

• Review of existing literature on erythropoietin (EPO) and recombinant EPO.
• Analysis of EPO's effects on RBC physiology and production pathways.
• Examination of clinical data regarding recombinant EPO efficacy, dosing, and adverse events.

Main Results:

• EPO production may be stimulated by oxygen consumption via a non-cAMP pathway.
• EPO prevents programmed cell death in early erythroid precursors (BFU-E and CFU-E).
• Recombinant EPO therapy in dialysis patients achieves an average hematocrit of 31%, with significant inter-patient variability in response and dosing requirements due to factors like RBC half-life and hyperparathyroidism.

Conclusions:

• Recombinant EPO is effective in treating renal anemia, but optimal target hematocrit for maximum patient benefit at acceptable cost is undetermined.
• Hypertension, potentially mediated by endothelin, occurs in 20-35% of patients receiving EPO.
• EPO therapy offers multi-organ benefits, including improved muscle metabolism, cardiac function, immune response, and brain electrophysiology.